Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Recently, to meet the funding needs for the business development of its subsidiaries, the Company has provided joint liability guarantees for the credit limits of its holding subsidiaries, Baiyang Yimei Technology Co., Ltd. (hereinafter referred to as "Baiyang Yimei") and Tiao Ti Miao Trading Co., Ltd. (hereinafter referred to as "Tiao Ti Miao"). The specific circumstances are as follows:
1. Overview of the Guarantees
The Company held the 31st meeting of the third Board of Directors on April 22, 2025, and the 2024 Annual General Meeting on May 14, 2025, where it reviewed and approved the proposal on the expected external guarantee limits for 2025. The Company agreed to provide a guarantee limit of no more than RMB 24 million for Baiyang Yimei and no more than RMB 44.4 million for Tiao Ti Miao, with the validity period of the guarantee limits being 12 months from the date of the resolution passed at the 2024 Annual General Meeting. For detailed information, please refer to the relevant announcements disclosed by the Company on the Giant Tide Information Network (www.cninfo.com.cn).